Sisuog...

Clinical trial identifies women most likely to benefit from vaginal mesh surgery

Certain women with vaginal prolapse are most likely to benefit from undergoing vaginal mesh surgery, a technique that has become controversial and is the focus of numerous lawsuits.

The findings, which are published early online in *Ultrasound in Obstetrics & Gynecology*, provide valuable information regarding who should and should not be considered candidates for the surgery.

Vaginal prolapse—when pelvic tissues weaken and the vaginal canal may protrude through the vaginal opening—affects roughly 10% to 20% of women. A significant number of patients require repeat surgeries to correct this recurring issue. They often undergo sacrospinous vaginal colpopexy—which involves attaching the vagina to surrounding tissue in the abdomen to hold it in place—or a surgical procedure that inserts a net-like implant called a vaginal mesh.

While studies suggest that vaginal mesh may reduce recurrence rates, it also has been linked with significant complications. (Indeed, vaginal mesh is the focus of a number of ongoing lawsuits.) To justify the potential complications associated with mesh use, it's important to identify women at high risk of prolapse recurrence.

Research suggests that a condition called levator avulsion is a major contributor to the development of pelvic floor prolapse and to its recurrence after surgery. This condition occurs when a woman suffers from an injury to the pelvic floor muscle during vaginal childbirth. This information led Kamil Svabík, MD, PhD, of Charles University and General University Hospital in Prague, and his colleagues to compare sacrospinous vaginal colpopexy with vaginal mesh in patients with post-hysterectomy prolapse and levator avulsion, as diagnosed by ultrasound imaging.

The randomized clinical trial included 70 women: 36 underwent vaginal mesh surgery and 34 underwent sacrospinous vaginal colpopexy. At the one-year follow-up, ultrasound examinations revealed that there was one recurrence in the vaginal mesh group (2.8%), and 21 recurrences in the sacrospinous vaginal colpopexy group (61.8%). Dr. Svabík noted that despite the study's small size, the team was able to achieve significant results.

"By assessing patients prior to receiving treatment using pelvic floor ultrasound imaging, we are able to identify women who will benefit from vaginal mesh implantation over a conventional approach and dramatically reduce the risk of repeat surgery," said Dr. Svabík. "This is a win/win situation for our patients and for understanding the reasons behind varying success rates of conventional or less traditional treatments."

ENDS

For more information, contact Matilda Sims, Communications Manager, at: E: msims@isuog.org T: +44 (0)20 74719955 Or visit our website: isuog.org

Sisuog...

Notes to Editors

Article:

"Comparison of vaginal mesh repair with sacrospinous vaginal colpopexy in the management of vaginal vault prolapse after hysterectomy in patients with levator ani avulsion: a randomized controlled trial".

Kamil Svabík, MD, PhD, Alois Martan, MD, PhD, Jaromir Masata, MD, PhD, Rachid El-Haddad, MD, and Petr Hubka MD, PhD. *Ultrasound in Obstetrics & Gynecology; Volume 43, Issue 3, Date: April 2014 Published early online, 11 March 2014*

Follow link for full article:

http://onlinelibrary.wiley.com/doi/10.1002/uog.13305/ abstract

About ISUOG:

1400 women die from pregnancy related causes every day, worldwide. The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) is dedicated to ensuring that all women have access to competent ultrasound and that obstetric and gynecological conditions are effectively diagnosed. ISUOG delivers high quality learning through its education program and World Congress and disseminates research information and clinical guidance through its journal *Ultrasound in Obstetrics & Gynecology*. With more than 7800 members across 126 countries, ISUOG is committed to improving health outcomes for women and their families across the world.

About Wiley:

Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.

Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.wiley.com.

